Pozen To Receive Additional $10 Million

Pozen Inc. (POZN) began a late stage trial of its anti-inflammation drug and will receive an additional $10 million from AstraZeneca PLC (AZN) on top of the original $335 million for the development of the treatment. Shares of Pozen jumped $2.78 to close at $12.76 while AstraZeneca stock eased 85 cents to close at $48.03.